L2167
L-165,041
≥98% (HPLC), powder
别名:
4-[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxyacetic acid
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C22H26O7
化学文摘社编号:
分子量:
402.44
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
Storage condition:
protect from light
under inert gas
under inert gas
产品名称
L-165,041, ≥98% (HPLC), powder
InChI key
HBBVCKCCQCQCTJ-UHFFFAOYSA-N
SMILES string
CCCc1c(O)c(ccc1OCCCOc2ccc(OCC(O)=O)cc2)C(C)=O
InChI
1S/C22H26O7/c1-3-5-19-20(11-10-18(15(2)23)22(19)26)28-13-4-12-27-16-6-8-17(9-7-16)29-14-21(24)25/h6-11,26H,3-5,12-14H2,1-2H3,(H,24,25)
assay
≥98% (HPLC)
form
powder
storage condition
protect from light
under inert gas
color
off-white
mp
127-128 °C (lit.)
solubility
DMSO: >10 mg/mL
originator
GlaxoSmithKline
storage temp.
2-8°C
Quality Level
Gene Information
human ... PPARD(5467)
Application
L-165,041 has been used as a peroxisome proliferator-activated receptor β/δ (PPARβ/δ) ligand to study its influence on PPARβ/δ mediated postnatal myogenesis in C2C12 myoblasts.
Biochem/physiol Actions
L-165041 dose-dependently blocks rat vascular smooth muscle cell (VSMC) proliferation and migration by inducing the cell cycle arrest. It has the potential to treat pathological cardiovascular conditions, such as restenosis and atherosclerosis. L-165041 also effectively inhibits the progression of diabetic nephropathy. It exhibits anti-apoptosis and anti-angiogenic effects.
PPARβ (PPARδ) selective agonist.
Features and Benefits
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
Jin-Hee Park et al.
Journal of cellular biochemistry, 113(6), 1947-1954 (2012-01-12)
Peroxisome proliferator-activated receptor (PPAR)δ is known to be expressed ubiquitously and involved in lipid and glucose metabolism. Recent studies have demonstrated that PPARδ is expressed in endothelial cells (ECs) and plays a potential role in endothelial survival and proliferation. Although
Jui-Ting Chang et al.
BMC pharmacology & toxicology, 18(1), 67-67 (2017-10-27)
Hyperglycemia-induced advanced glycation end products (AGEs) and receptor for AGEs (RAGE) production play major roles in progression of diabetic nephropathy. Anti-RAGE effect of peroxisome proliferator-activated receptor-delta (PPARδ) agonists was shown in previous studies. PPARδ agonists also stimulate glucagon-like peptide-1 (GLP-1)
Hyun-Joung Lim et al.
Atherosclerosis, 202(2), 446-454 (2008-07-01)
The peroxisome proliferator-activated receptor (PPAR) family of nuclear hormone receptors consists of three subtypes (alpha, beta/delta, and gamma). PPAR delta is ubiquitously expressed and involved in lipid and glucose metabolism. However, the effect of PPAR delta on vascular smooth muscle
Yao-Jen Liang et al.
European journal of pharmacology, 715(1-3), 33-38 (2013-07-09)
Diabetic nephropathy is the leading cause of end-stage renal disease in the most developed countries of the world. Hyperglycemia-induced advanced glycation end products (AGEs) and receptor for AGEs (RAGE) production, pro-inflammatory cytokine secretion, and oxidative stress activation play major roles
Jun-Yang Liou et al.
Arteriosclerosis, thrombosis, and vascular biology, 26(7), 1481-1487 (2006-04-29)
To determine the role of prostacyclin (PGI2) in protecting endothelial cells (ECs) from apoptosis and elucidate the protective mechanism. To evaluate the effect of PGI2 on EC survival, we treated ECs with Ad-COX1/PGIS (Ad-COPI), which augmented selectively PGI2 production or
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持